在患有暂时机械循环支持的患者中, angiotensin II 1 型受体抗体的发展
Maria T Gamero1, Mark Liotta1, Yevgeniy Brailovsky1
1Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
JHLT open
|March 27, 2025
概括
暂时的机械循环支持 (MCS) 可以影响心脏移植候选人的抗体发育. 冲动器设备与高发生率的血管新素II类型1受体抗体 (AT1R-Ab) 相关,与大动脉内气球不同.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 移植 移植 移植 移植
背景情况:
- ангиотензин II 1 型受体抗体 (AT1R-Ab) 与固体器官移植功能障碍有关.
- 暂时机械循环支持 (MCS) 在自身抗体发育中的作用尚不清楚.
- 目前的心脏移植分配优先考虑需要临时MCS的患者.
研究的目的:
- 研究心脏移植候选人中AT1R-Ab的发展,这些候选人需要暂时的MCS.
- 为了比较Impella和大动脉内气球支之间的AT1R-Ab发展.
主要方法:
- 对10名临时MCS心脏移植候选人的前性研究.
- 患者接受了Impella (n=8) 或大动脉内气球 (n=2) 的支持.
- 在MCS支持期间监测AT1R-Ab水平.
主要成果:
- 87.5%的Impella患者 (7/8) 发展出AT1R-Ab;其中一个是边界.
- 在大动脉内气球患者中没有观察到AT1R-Ab的发展 (0/2).
- 建议在Impella的内皮切割应力和AT1R-Ab发展之间存在潜在的联系.
结论:
- 暂时的MCS,特别是Impella,可能会诱导心脏移植候选人的AT1R-Ab发展.
- 这些发现突显了临时MCS设备的潜在免疫学影响.
- 需要进一步的研究来证实这种关联和潜在的机制.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
Antihypertensive Drugs: Angiotensin II Receptor Blockers
560
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
560
Antihypertensive Drugs: Direct Renin Inhibitors
466
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
466
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
430
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
430
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
118
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
118


